Introduction
Chronic myeloid leukemia (CML) is characterized cytogenetically by a reciprocal t(9;22)(q34;q11) chromosomal translocation that leads to the formation of the Philadelphia (Ph) chromosome containing the BCR-ABL oncogene.
1 BCR-ABL encodes a constitutively activate tyrosine kinase responsible for the clinical features of leukemia. 2 The multilineage nature of CML indicates that human stem cells are critical targets of this disease. Furthermore, the Ph chromosome is found in all hematopoietic lineages. [3] [4] [5] [6] [7] [8] Despite this, in the chronic phase (CP) of CML, leukemic stem cells can differentiate, and mature neutrophils dominate the peripheral blood and bone marrow. Therefore, it follows that BCR-ABL preferentially promotes granulocytic differentiation and Ph-positive leukemic stem cell proliferation, possibly through the constitutive expression of growth-stimulating factors by leukemic progenitors and through the anti-apoptotic properties of CML cells. [9] [10] [11] The loss of expression of CCAAT/enhancer-binding protein (C/EBP)a, which plays a critical role in granulocytic differentiation, contributes to the aggressive proliferation of immature cells in CML, known as blastic crisis (BC). [12] [13] [14] [15] How altered transcriptional regulation drives BCR-ABL-transformed stem cells to differentiate mainly into mature neutrophils is not understood. However, deficiencies in transcription factors, including interferon consensus sequence binding protein or JunB, can result in CML-like disease in animal models. [16] [17] [18] [19] Neutrophil gene expression profiles have been successfully used to describe the molecular etiology underlying disease development in other myeloid malignancies. [20] [21] [22] Therefore, we used an oligonucleotide microarray to compare the gene expression profiles of neutrophils from CML-CP patients and from healthy volunteers. We analyzed the role of the transcription factor c-Jun, which plays an important role in monocytic differentiation, [23] [24] [25] [26] [27] [28] [29] in determining the differentiation lineages in CML-CP.
Materials and methods

Isolation of peripheral blood neutrophils and total RNA
The study protocol was approved by the local ethics committee. After informed consent, neutrophils were isolated 30 from the peripheral blood samples of 14 CML-CP patients and 8 healthy individuals. Neutrophils were purified (496% purity based on visual inspection of Wright Giemsa (WG)-stained slide preparations) using CD16 magnetic beads (Miltenyi, Bergisch Gladbach, Germany). Total RNA was isolated from purified cell populations using ISOGEN (Nippon Gene, Tokyo, Japan). To remove genomic DNA, 200 U of DNase I (Sigma-Aldrich, St. Louis, MO, USA) were incubated with the isolated total RNA for 30 min at 37 1C. Total RNA was purified using an RNeasy Mini Kit (Qiagen, Hilden, Germany). Equal amounts of RNA extracted from the neutrophil fraction from eight healthy volunteers were mixed to generate a pool of normal control RNA.
Microarray analysis
Oligonucleotide microarray analysis with ScanArray Express software (PerkinElmer, Wellesley, MA, USA) was performed 21 using Panorama Microarray gene expression chips, each containing B30 000 probe sets (Sigma-Aldrich) according to the manufacturer's instructions. For mean-fold expression changes in gene lists, the average expression values of genes from the CML-CP patients were used. P-values were calculated by Student's t-test by performing pairwise comparisons with a control gene (glucose-6-phosphate dehydrogenase). We further analyzed transcription factor genes that are reportedly critical for hematopoietic differentiation, by modifying a previously published list. 31 Genes were hierarchically clustered using TIGR MeV software (www.tigr.org/software/tm4/).
Real-time quantitative RT-PCR (qRT-PCR) and RT-PCR
Real-time qRT-PCR analysis was performed in triplicate in the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and the Light Cycler 480 (Roche, Mannheim, Germany) using Universal ProbeLibrary probes (Roche). Glucose-6-phosphate dehydrogenase was used to normalize the results of real-time qRT-PCR. The expression analysis of myeloid markers by RT-PCR was performed as published earlier. 15 The conditions and primer sequences are available upon request.
Plasmids and transfections
Zinc-inducible C/EBPa expression vectors (pMEP4a) were constructed from a pMEP4 plasmid (Invitrogen, Carlsbad, CA, USA) and used to transfect KCL22 cells derived from CML patients in BC (Dr H Mano, Jichi Medical School, Tochigi, Japan), to form KCL22/a. Cells were cultured in RPMI 1640 (Sigma-Aldrich) containing 10% heat-inactivated fetal bovine serum (Thermo, Melbourne, Australia). Transfection was performed using Lipofectamine 2000 (Invitrogen). To obtain stably transfected cells, the cells were selected with hygromycin (400 mg/ml) 48 h after transfection.
Western blot analysis
Total cell lysates (from 5 Â 10 5 cells) were transferred to membranes (Bio-Rad, Hercules, USA) and incubated for 1 h with primary antibodies [(goat polyclonal anti-C/EBPa (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse polyclonal anti-c-Jun (BD Biosciences, San Jose, CA, USA)] followed by a secondary horseradish peroxidase-conjugated antibody (Santa Cruz Biotechnology). Detection was performed using ECL Plus Western blotting detection reagents (Amersham Biosciences, Buckinghamshire, UK) with an LAS-1000 image analyzer (FUJIFILM).
Short interfering RNA transfection
Double-stranded 21-nt short interfering RNA (siRNAs) directed at human c-Jun mRNA were chemically synthesized (Dharmacon, Lafayette, IN, USA). The sense cDNA sequences were UGG AAA CGA CCU UCU AUG AUU for siRNA-1, GAG CUG GAG CGC CUG AUA AUU for siRNA-2, UAA CGC AGC AGU UGC AAA CUU for siRNA-3, and GAG CGG ACC UUA UGG CUA CUU for siRNA-4. The BLOCK-iT fluorescence system (Invitrogen) was used to analyze the transfection efficacy and as a negative control. Cells cultured with 1.0 mM imatinib and 100 mM ZnSO 4 for 24 h were collected by centrifugation and then resuspended in new medium (5 Â 10 5 cells/ml). A mixture of four siRNA sequences (100 nM) was transfected using Lipofectamine 2000, and c-Jun knockdown was confirmed 48 h after siRNA transfection by western blot analysis.
Flow cytometry
For each flow cytometry analysis, 10 6 cells were washed with washing buffer and incubated at 4 1C for 20 min in 20 ml of either a mouse polyclonal G-CSFR antibody (Serotec, Kidlington, UK) or a mouse IgG1 antibody (Dako, Glostrup, Denmark; negative control) or in 5 ml of propidium iodide (PI) (BD, Franklin Lakes, NJ, USA) to detect apoptotic cells. Cells were re-washed in washing buffer, resuspended, and analyzed by flow cytometry (FACSCalibur, BD Biosciences).
Cell morphologic and cytochemical analyses
Cellular morphologies were studied after WG staining of cytospin slides. Cytochemical double esterase (DE) staining of cytospin slides was performed with naphthol AS-D chloroacetate esterase (NASDA) and a-naphthyl butyrate esterase (a-NB). 
Results and Discussion
Gene expression profiles of CML versus those of normal neutrophils
The expression levels of 183 genes (107 upregulated at least 2-fold and 76 downregulated at least 1.5-fold) were significantly different between CML neutrophils and normal neutrophils, using 0.05 P cutoff values ( Supplementary Tables 1 and 2 ). Among the genes overexpressed in CML neutrophils were defensin, lactotransferrin, neutrophil elastase, bactericidal/ permeability increasing protein, transcobalamin I, haptoglobin, cathelicidin antimicrobial peptide, and cathepsin G. As differentiation progressed, these lineage-specific genes encode neutrophil granule proteins in azurophilic, secondary, or gelatinase granules. As neutrophil granule protein expression is regulated by C/EBPs, we performed a separate statistical analysis of transcription factor gene expression. C/EBPa and C/EBPe were upregulated in CML neutrophils, while interferon consensus sequence binding protein and the monopoiesisrelated transcription factor c-Jun were downregulated (Supplementary Figure 1 ). c-Jun and C/EBPa are reportedly mutually antagonistic in the lineage commitment of granulocyte-monocyte progenitor cells. 32, 33 Recent studies also indicate that C/EBPa functions as a master regulator of granulocyte and monocyte lineage commitment, depending on the expression levels of PU.1 and c-Jun. 34, 35 c-Jun expression does not dramatically change in normal granulocytic differentiation, but does increase slightly in the late stage of differentiation. 31 The continuous downregulation of c-Jun expression in CML-CP likely biases the lineage commitment towards the granulocytic lineage rather than towards monopoiesis. The requirement for c-Jun in normal erythropoiesis 36 might explain the CML-CP phenotype in which c-Jun expression is inhibited and the Ph chromosome-containing erythroid progenitor does not expand. 
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The decreased levels of alkaline phosphatase observed in CML neutrophils, both in our study (data not shown) and in clinical observations, suggest that these neutrophils are not completely mature. However, the observed increases in the expression of C/EBPa and neutrophil granule proteins indicate that CML neutrophils may have a greater than normal functionality. C/EBPa is reportedly required to direct cell fate to the myeloid lineage in BCR-ABL-induced malignant hematopoiesis, 37 indicating that the role of C/EBPa in lineage commitment is similar in malignant and in normal hematopoieses. The activity of lineage-determining transcription factors such as C/EBPa may preferentially commit CML progenitors to the granulocytic cell fate in CML-CP. Therefore, we hypothesize that altered expression of these transcription factors contributes to the CML-CP disease phenotype.
BCR-ABL downregulates c-Jun expression in CML cells
Real-time qRT-PCR in five CML patients revealed that C/EBPa was overexpressed by 3.18-fold (mean value) and c-Jun was downregulated by 4.27-fold (mean value) in CML neutrophils, which is consistent with our microarray results ( Figure 1a) . We analyzed BCR-ABL-mediated c-Jun regulation in three CML patients. Imatinib increased c-Jun expression in primary CML neutrophils compared with control cultures (Figure 1b) , while C/EBPa expression levels did not significantly change (data not shown). Although C/EBPa expression might be increased through BCR-ABL regulation, alternatively, a secondary mechanism might maintain C/EBPa expression during terminal differentiation. Imatinib reversed c-Jun downregulation in BCR-ABL-positive KCL22 and K562 cells, that, like KCL22 cells, are derived from CML patients, but did not alter the expression levels (compared with control) in the Ph-negative leukemia cell lines NB40, U937, or ML-1 (Figure 1c) . Imatinib did not recover C/EBPa expression in KCL22 cells (data not shown). Microarray analyses have previously shown that BCR-ABL suppression by siRNA or imatinib upregulates c-Jun expression in K562 cells. 38, 39 Together with our results, this suggests that c-Jun downregulation by BCR-ABL is a specific property of CML cells.
Establishment of a myeloid differentiation model of BCR-ABL-positive cells
We established a myeloid differentiation model using KCL22 cells with zinc-inducible C/EBPa (KCL22/a). Three independent clones of KCL22/a were cultured in zinc-deficient media for 16 h (Supplementary Figure 2a) . After 7 d in a zinc-containing media, most cells had a reduced nucleus-to-cytoplasm ratio and more condensed nuclear chromatin, and many had stab or segmented nuclei, typical of mature neutrophils ( Supplementary  Figure 2b) . Mock-transfected KCL22 (KCL22/MOCK) cells grown in the presence of ZnSO 4 (Supplementary Figure 2b) and KCL22/a cells grown without ZnSO 4 (data not shown) had a characteristic myeloblastic appearance and were indistinguishable from untransfected KCL22 cells. After 7 d of culture in zinc-containing medium, the transcript levels of the neutrophil-specific genes MPO, G-CSFR, lactotransferrin, and MMP9 were dramatically increased in KCL22/a cells (Supplementary Figure 2c) . . Without C/EBPa induction, monocytic differentiation after imatinib treatment was apparent; cells were diffusely, but weakly, positive for a-NB but not for NASDA ( Figure 2B, DE panel) . Increased expression levels of CD11c and c-fms, markers for monocytic differentiation, were also observed after incubation of C/EBPainduced KCL22/a cells with imatinib ( Figure 2D ). The apoptotic and anti-proliferative effects of imatinib and/or C/EBPa were also clearly observed (data not shown). The apoptotic level of untransfected KCL22 cells treated with imatinib was similar to that of KCL22/a cells (23 and 26%, respectively). Finally, flow cytometry revealed a positive shift in the G-CSFR peak 3 days after siRNA-induced c-Jun knockdown in KCL22/a cells ( Figures  2E and F) , indicating that c-Jun downregulation by BCR-ABL specifically promotes granulocytic differentiation in CML. This regulation of differentiation shows that BCR-ABL-mediated c-Jun downregulation is a key event for the promotion of granulocytic differentiation in CML-CP.
BCR-ABL
BCR-ABL downregulates c-Jun expression through the PI3K-Akt pathway
We next investigated which BCR-ABL-activated pathway regulates c-Jun expression. Treatment of KCL22 cells with Akt inhibitor IV or LY294002 increased c-Jun expression similar to imatinib treatment (Figure 3a) , and Akt inhibitor IV also increased CD11c and c-fms expression in KCL22 and K562 cells (Figure 3b ). CD11c levels were likewise increased after Akt inhibitor IV treatment of C/EBPa induced KCL22/a cells (Figure 3c ). The impact of the activated PI3K-Akt signaling pathway on CML cell differentiation has been unclear. Our results show that the BCR-ABL-activated PI3-Akt pathway regulates c-Jun downregulation, and that c-Jun upregulation following PI3-Akt pathway inhibition preferentially reverses the monocytic differentiation of CML cells.
Conclusion
Our findings suggest that the BCR-ABL gene fusion product is a constitutively active tyrosine kinase that downregulates c-Jun expression. We hypothesize that a balance between c-Jun and C/EBP expression levels is crucial for determining the disease phenotype in CML-CP, and that BCR-ABL is directly involved in maintaining this balance, given its ability to downregulate c-Jun expression though the PI3K-Akt pathway.
